M. Del Prete
Marche Polytechnic University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by M. Del Prete.
Annals of Oncology | 2014
Riccardo Giampieri; M. Del Prete; Fotios Loupakis; Lisa Salvatore; Tiziana Prochilo; Luca Faloppi; Giuseppe Aprile; Maristella Bianconi; Alessandro Bittoni; Alfredo Falcone; Alberto Zaniboni; Mario Scartozzi; Stefano Cascinu
ABSTRACT Aim: A non-negligible proportion of colorectal cancer patients receiving regorafenib does not seem to benefit from such a treatment approach and are then exposed to unnecessary toxicity. Neutrophil/lymphocyte ratio and piastrinosis (platelet number increase) may represent indirect indicator of tumour induced inflammation and angiogenesis and have been suggested to influence patients’ outcome. Our analysis investigated the role of neutrophil/lymphocyte ratio and piastrinosis in pretreated metastatic colorectal cancer patients receiving regorafenib. Methods: We collected neutrophil, lymphocyte and platelet count at the start of treatment. Cut-off values for neutrophil/lymphocyte ratio and platelets were calculated by ROC curve analysis. Other tested variables were: age, sex, performance status, k-ras status, number of metastatic sites, previous adjuvant chemotherapy, number of previous systemic anticancer therapies, Overall survival (OS) and progression free survival (PFS) were calculated by Kaplan-Meier method, multivariate analysis was performed by Cox method. Results: 208 patients were eligible. In the global population median OS was 4.2 months whereas median PFS was 2.4 months. Ten (5%) achieved a partial response, 58 (29%) disease stabilization and the remaining 134 (66%) progressed under treatment. The cut off value for piastrinosis and neutrophil/lymphocyte ratio was determined at 0.545 ULN and 0.381 respectively. At univariate analysis neutrophil/lymphocyte ratio and piastrinosis both correlated with clinical outcome. At multivariate analysis a high platelet count and high neutrophil/lymphocyte ratio were related to a worse OS (Exp(b):1.49, 95%CI:1.0130-2.2103, p = 0.0439 and Exp(b):1.6963, 95%CI: 1.0757-2.6751, p = 0.0237 respectively) and PFS (Exp(b):1.4985, 95% CI: 1.0925-2.0556, p = 0.0126 and Exp(b): 1.9277, 95% CI: 1.3226-2.8097, p = 0,0007 respectively). Interestingly in 52 (25%) patients negative for these factors, median overall survival was 15.9 months vs. 3.1 months for patients harbouring at least one of the factors examined (HR:3.81, 95% CI:2.3260-4.8274, p Conclusions: Our analysis suggests that a high platelet count and a high neutrophil/lymphocyte ratio are predictive factors for clinical outcome in patients treated with regorafenib. Disclosure: All authors have declared no conflicts of interest.
Annals of Oncology | 2017
Luca Cantini; Riccardo Giampieri; M Palladino; M. Del Prete; Alessandro Bittoni; E Giglio; Tania Meletani; G M Baleani; Elena Maccaroni; M Di Pietro Paolo; Rossana Berardi
Annals of Oncology | 2017
Elena Maccaroni; Riccardo Giampieri; M. Del Prete; G Principi; R. Bracci; A Calcinari; A. Della Mora; F. Bianchi; L. Belvederesi; C. Brugiati; Silvia Pagliaretta; Mirco Pistelli; Agnese Savini; A. Pagliacci; Z. Ballatore; F Bini; Maria Giuditta Baleani; Luca Cantini; A Murrone; Rossana Berardi
Annals of Oncology | 2017
Riccardo Giampieri; Andrea Lanese; G Pusole; M. Del Prete; Alessandro Bittoni; Luca Cantini; Elena Maccaroni; Valeria Pusceddu; S Delprete; Miriam Caramanti; Tania Meletani; Maria Giuditta Baleani; M Di Pietro Paolo; Mario Scartozzi; Rossana Berardi
Journal of Hepatology | 2015
Luca Faloppi; M. Del Prete; Maristella Bianconi; Daniele Santini; Nicola Silvestris; A. Casadei Gardini; Oronzo Brunetti; Riccardo Giampieri; Mario Scartozzi; Stefano Cascinu
Journal of Hepatology | 2015
Luca Faloppi; Maristella Bianconi; G. Svegliati Baroni; A. Casadei Gardini; Nicola Silvestris; Gianluca Masi; Paola Ulivi; Caterina Vivaldi; Riccardo Giampieri; M. Del Prete; Antonio Benedetti; Mario Scartozzi; Stefano Cascinu
European Journal of Cancer | 2015
Maristella Bianconi; Luca Faloppi; Antonio Zizzi; R. Mazzucchelli; Riccardo Giampieri; Alessandro Bittoni; Kalliopi Andrikou; M. Del Prete; Mario Scartozzi; Rodolfo Montironi; S. Cascinu
European Journal of Cancer | 2015
Luca Faloppi; M. Del Prete; A. Casadei Gardini; Daniele Santini; Nicola Silvestris; Maristella Bianconi; Riccardo Giampieri; Alessandro Bittoni; Kalliopi Andrikou; Martina Valgiusti; Oronzo Brunetti; Mario Scartozzi; S. Cascinu
Annals of Oncology | 2015
Riccardo Giampieri; M. Del Prete; Luca Faloppi; Maristella Bianconi; Kalliopi Andrikou; Alessandro Bittoni; Elena Maccaroni; S. Cascinu
Annals of Oncology | 2015
Alessandro Bittoni; Kalliopi Andrikou; Matteo Santoni; Riccardo Giampieri; Alessandra Mandolesi; Chiara Pellei; Luca Faloppi; Cristian Loretelli; Andrea Lanese; M. Del Prete; Elena Maccaroni; Maristella Bianconi; Stefano Cascinu